Prostate cancer prostate cancer, PSMA, PET
Conditions
Interventions
In-house manufactured [68Ga] PSMA-11 is administered intravenously and PET/CT scans are performed.
Sponsors
Shiroki Ryoichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have been fully informed of the study and have given their voluntary written consent based on their full understanding. 2. Patients aged 20 to 85 years at the time of consent 3. Patients diagnosed with high-risk localized prostate cancer 4. Patients with PSA recurrence after curative treatment for localized prostate cancer 5. Patients diagnosed with non-metastatic castration-resistant prostate cancer 6. Patients diagnosed with metastatic castration-resistant prostate cance
Exclusion criteria
Exclusion criteria: 1. Patients who have difficulty maintaining a supine position for the duration of the examination (approximately 20 minutes). 2. Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events after administration of [68Ga]PSMA-11, including fatigue, nausea, constipation, and vomiting | — |
Contacts
Public ContactRyoichi Shiroki
Fujita Health University Hospital
Outcome results
None listed